Observational Study to evaluate the effect and safety of Selumetinib in Pediatric Patients with NF1-PNs

Trial Identifier:	D1346R00016
Sponsor:	AstraZeneca
NCTID::	NCT06175637
Start Date:	December 2023
Primary Completion Date:	July 2027
Study Completion Date:	July 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China, Beijing	Beijing, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.